TY  - JOUR
AU  - Redondo, Alba M
AU  - Valcárcel, David
AU  - González-Rodríguez, Ana P
AU  - Suárez-Lledó, María
AU  - Bello, José L
AU  - Canales, Miguel
AU  - Gayoso, Jorge
AU  - Colorado, Mercedes
AU  - Jarque, Isidro
AU  - Del Campo, Raquel
AU  - Arranz, Reyes
AU  - Terol, María J
AU  - Rifón, José J
AU  - Rodríguez, María J
AU  - Ramírez, María J
AU  - Castro, Nerea
AU  - Sánchez, Andrés
AU  - López-Jiménez, Javier
AU  - Montes-Moreno, Santiago
AU  - Briones, Javier
AU  - López, Aurelio
AU  - Palomera, Luis
AU  - López-Guillermo, Armando
AU  - Caballero, Dolores
AU  - Martín, Alejandro
AU  - Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO)
PY  - 2018
DO  - 10.1111/bjh.15713
UR  - https://hdl.handle.net/10668/25042
T2  - British journal of haematology
AB  - We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen (BendaEAM) as conditioning for autologous stem-cell transplantation (ASCT) in...
LA  - en
KW  - BEAM
KW  - aggressive lymphomas
KW  - autologous stem-cell transplantation
KW  - bendamustine
KW  - clinical trial
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Autografts
KW  - Bendamustine Hydrochloride
KW  - Carmustine
KW  - Cytarabine
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Lymphoma
KW  - Male
KW  - Melphalan
KW  - Middle Aged
KW  - Peripheral Blood Stem Cell Transplantation
KW  - Podophyllotoxin
KW  - Survival Rate
KW  - Transplantation Conditioning
TI  - Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
TY  - research article
VL  - 184
ER  -